InVitro International (IVRO)
USD 0.1
(9.67%)
USD 0.1
(9.67%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -25.33 Thousand USD | 78.3% |
| 2022 | -116.77 Thousand USD | -335.87% |
| 2021 | -26.79 Thousand USD | -185.62% |
| 2020 | 31.29 Thousand USD | -48.35% |
| 2019 | 60.58 Thousand USD | 45.17% |
| 2018 | 41.73 Thousand USD | 10.05% |
| 2017 | 37.92 Thousand USD | -64.79% |
| 2016 | 107.7 Thousand USD | -52.38% |
| 2015 | 226.18 Thousand USD | 1139.16% |
| 2014 | 18.25 Thousand USD | 0.0% |
| 1996 | -2.1 Million USD | 34.38% |
| 1995 | -3.2 Million USD | 33.33% |
| 1994 | -4.8 Million USD | -33.33% |
| 1993 | -3.6 Million USD | 34.55% |
| 1992 | -5.5 Million USD | -66.67% |
| 1991 | -3.3 Million USD | -3400.0% |
| 1990 | 100 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 8560.00 USD | -78.89% |
| 2024 Q2 | 38.06 Thousand USD | 344.63% |
| 2024 Q3 | 6430.00 USD | -83.11% |
| 2023 Q2 | -15.46 Thousand USD | 50.4% |
| 2023 Q4 | 40.55 Thousand USD | 310.54% |
| 2023 Q1 | -31.17 Thousand USD | 65.06% |
| 2023 Q3 | -19.26 Thousand USD | -24.58% |
| 2023 FY | -25.34 Thousand USD | 78.3% |
| 2022 Q3 | 11.84 Thousand USD | -45.89% |
| 2022 FY | -116.77 Thousand USD | -335.87% |
| 2022 Q1 | -61.28 Thousand USD | -558.68% |
| 2022 Q2 | 21.88 Thousand USD | 135.7% |
| 2022 Q4 | -89.21 Thousand USD | -853.46% |
| 2021 Q2 | -54.54 Thousand USD | 0.0% |
| 2021 FY | -26.79 Thousand USD | -185.62% |
| 2021 Q4 | 13.36 Thousand USD | -82.08% |
| 2021 Q3 | 74.54 Thousand USD | 236.67% |
| 2020 FY | 31.29 Thousand USD | -48.35% |
| 2019 FY | 60.58 Thousand USD | 45.17% |
| 2018 FY | 41.73 Thousand USD | 10.05% |
| 2017 FY | 37.92 Thousand USD | -64.79% |
| 2016 FY | 107.7 Thousand USD | -52.38% |
| 2015 FY | 226.18 Thousand USD | 1139.16% |
| 2014 FY | 18.25 Thousand USD | 0.0% |
| 1997 Q2 | 403 Thousand USD | 34.33% |
| 1997 Q3 | -201 Thousand USD | -149.88% |
| 1997 Q1 | 300 Thousand USD | 150.0% |
| 1996 Q3 | -400 Thousand USD | 20.0% |
| 1996 Q4 | -600 Thousand USD | -50.0% |
| 1996 Q1 | -600 Thousand USD | 84.21% |
| 1996 Q2 | -500 Thousand USD | 16.67% |
| 1996 FY | -2.1 Million USD | 34.38% |
| 1995 Q2 | 200 Thousand USD | -33.33% |
| 1995 FY | -3.2 Million USD | 33.33% |
| 1995 Q4 | -3.8 Million USD | -1366.67% |
| 1995 Q3 | 300 Thousand USD | 50.0% |
| 1995 Q1 | 300 Thousand USD | 121.43% |
| 1994 Q4 | -1.4 Million USD | -16.67% |
| 1994 Q1 | -1 Million USD | 9.09% |
| 1994 Q2 | -1 Million USD | 0.0% |
| 1994 Q3 | -1.2 Million USD | -20.0% |
| 1994 FY | -4.8 Million USD | -33.33% |
| 1993 Q1 | -700 Thousand USD | 41.67% |
| 1993 Q3 | -700 Thousand USD | 30.0% |
| 1993 Q4 | -1.1 Million USD | -57.14% |
| 1993 FY | -3.6 Million USD | 34.55% |
| 1993 Q2 | -1 Million USD | -42.86% |
| 1992 Q2 | -1.7 Million USD | -950.0% |
| 1992 FY | -5.5 Million USD | -66.67% |
| 1992 Q4 | -1.2 Million USD | 20.0% |
| 1992 Q3 | -1.5 Million USD | 11.76% |
| 1992 Q1 | 200 Thousand USD | 133.33% |
| 1991 Q3 | -500 Thousand USD | 37.5% |
| 1991 FY | -3.3 Million USD | -3400.0% |
| 1991 Q4 | -600 Thousand USD | -20.0% |
| 1991 Q2 | -800 Thousand USD | -366.67% |
| 1991 Q1 | 300 Thousand USD | 0.0% |
| 1990 Q2 | -500 Thousand USD | -600.0% |
| 1990 FY | 100 Thousand USD | 0.0% |
| 1990 Q1 | 100 Thousand USD | 0.0% |
| 1990 Q3 | 300 Thousand USD | 160.0% |
| 1990 Q4 | 300 Thousand USD | 0.0% |
| 1989 Q3 | 100 Thousand USD | 0.0% |
| 1989 Q4 | 100 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.24 Million USD | 97.96% |
| Arrayit Corporation | -3.62 Million USD | 99.301% |
| Atlantic International Corp. | -5.73 Million USD | 99.558% |
| Biocept, Inc. | -31.98 Million USD | 99.921% |
| Bioqual, Inc. | -19.63 Thousand USD | -29.03% |
| CardioGenics Holdings Inc | -772.14 Thousand USD | 96.718% |
| DermTech, Inc. | -103.73 Million USD | 99.976% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion USD | 100.001% |
| HTG Molecular Diagnostics, Inc. | -20.82 Million USD | 99.878% |
| iMD Companies, Inc. | -175.44 Thousand USD | 85.557% |
| IDenta Corp. | -1499.00 USD | -1590.394% |
| Interpace Biosciences, Inc. | 2.8 Million USD | 100.904% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 165.492% |
| Lumos Diagnostics Holdings Limited | -7.12 Million USD | 99.644% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | 56.396% |
| Medical Imaging Corp. | -819.48 Thousand USD | 96.908% |
| NovelStem International Corp. | -3.52 Million USD | 99.281% |
| Optigenex Inc. | 1.39 Million USD | 101.822% |
| PharmChem, Inc. | 973.14 Thousand USD | 102.604% |
| Proteome Sciences plc | -1.62 Million USD | 98.437% |
| Response Genetics, Inc | -21.37 Million USD | 99.881% |
| Rennova Health, Inc. | -1.4 Million USD | 98.202% |
| RushNet, Inc. | -684.7 Thousand USD | 96.299% |
| ScreenPro Security Inc. | -2.59 Million USD | 99.023% |
| Stella Diagnostics Inc. | -11.42 Million USD | 99.778% |
| StageZero Life Sciences Ltd. | -7.74 Million USD | 99.673% |
| Todos Medical Ltd. | -9.74 Million USD | 99.74% |